Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00663767
Other study ID # ARRAY-797-222
Secondary ID C4411009
Status Completed
Phase Phase 2
First received
Last updated
Start date April 7, 2008
Est. completion date June 20, 2008

Study information

Verified date February 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled in this study.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date June 20, 2008
Est. primary completion date June 20, 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Key Inclusion Criteria: - Scheduled for outpatient oral surgical procedure to remove 3 or more third molars, at least 1 of which is mandibular and fully or partially impacted by bone. - Females of childbearing potential must be willing to use an acceptable method of contraception within 14 days prior to first dose of study drug until the completion of the follow-up procedures. - Body weight >50 kg (110 lbs). - Good health determined by medical history, physical examination, vital signs and clinical laboratory results of non-clinical significance. - Additional criteria exist. Key Exclusion Criteria: - Evidence or history of clinically significant dermatologic, hematological, renal, endocrine (e.g. poorly controlled diabetes), pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, ophthalmologic, or allergic disease (including clinically significant drug allergies that could impact the conduct of this study, but excluding untreated, asymptomatic, seasonal allergies at time of study drug dosing). - Positive urine drug screen within 28 days prior to first dose of study drug. - Use of prohibited prescription drugs, or grapefruit juice within 7 days of first dose of study drug; prohibited medications are defined as nonsteroidal and steroidal antiinflammatory drugs, analgesics including opioids (except low dose aspirin for myocardial infarction prophylaxis), P450 CYP3A substrates or inhibitors (strong or moderate). - Additional criteria exist.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo; oral
dose 1, dose 2
Placebo; oral
dose 1
ARRY-371797, p38 inhibitor; oral
dose 1: multiple dose levels
ARRY-371797, p38 inhibitor; oral
dose 1: multiple dose levels; dose 2
Celecoxib, COX-2 inhibitor; oral
dose 1
Placebo; oral
dose 2
ARRY-371797, p38 inhibitor; oral
dose 2

Locations

Country Name City State
United States PPD Phase I Clinic Austin Texas
United States Lifetree Clinical Research Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the efficacy of the study drug dosed postoperatively in terms of total pain relief (TOTPAR). 6 hours post-dose
Primary Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, electrocardiograms and vital signs. Duration of study
Secondary Assess the efficacy of the study drug (versus placebo and celecoxib) in terms of pain relief measurements [including TOTPAR, total pain intensity (TPI) and time to rescue medication]. Duration of study
See also
  Status Clinical Trial Phase
Completed NCT00942448 - Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery Phase 3
Completed NCT00943098 - Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery Phase 3
Completed NCT00985439 - Study of Diclofenac Capsules to Treat Dental Pain Phase 2
Completed NCT00954356 - Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction Phase 2
Completed NCT02966067 - A Split Mouth Trial to Compare Microneedles vs. Standard Needles in Dental Anaesthetic Delivery N/A
Completed NCT01960114 - Study of Long-Acting Acetaminophen in Postoperative Dental Pain Phase 2
Completed NCT01229228 - Study of Naproxen Capsules to Treat Dental Pain Phase 2
Completed NCT01177423 - Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block N/A
Completed NCT03328208 - Nonpharmacologic Reduction of Periprocedural Distress and Drug Use N/A
Completed NCT05236101 - Validation of Child Drawing Hospital Scale (CD: H) and the Place of the Drawing in the Evaluation of Dental Anxiety N/A
Completed NCT00542035 - A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction Phase 2
Completed NCT04231955 - Comparison of Different Pain Rating Scales in Patients With Symptomatic Teeth N/A
Completed NCT02096926 - Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery Phase 4
Completed NCT05369936 - Pain Perception: on Relationships Between Dental Anxiety and Olfaction N/A
Recruiting NCT05351099 - Dental Block for Pain Relief in ED Dental Pain Patients
Not yet recruiting NCT06269406 - A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults N/A
Recruiting NCT05443009 - Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction Phase 4
Terminated NCT02161354 - Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars Phase 2
Completed NCT04949126 - Self Medication in Odontology (AUDE)
Completed NCT03652818 - Dental Pain Study of Analgesics in Patients Undergoing Molar Removal Phase 2

External Links